172 related articles for article (PubMed ID: 31391830)
21. Cervical cancer in Latin America and the Caribbean: the problem and the way to solutions.
Villa LL
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1409-13. PubMed ID: 22956726
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis.
Tejada RA; Malagón T; Franco EL
Vaccine; 2022 Apr; 40(19):2667-2678. PubMed ID: 35370017
[TBL] [Abstract][Full Text] [Related]
24. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
25. [Prenatal care in Latin America].
Buekens P; Hernández P; Infante C
Salud Publica Mex; 1990; 32(6):673-84. PubMed ID: 2089644
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
27. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
[TBL] [Abstract][Full Text] [Related]
28. Tenth Technical Advisory Group (TAG) meeting on vaccine-preventable diseases.
EPI Newsl; 1992 Apr; 14(2):2-6. PubMed ID: 12285738
[TBL] [Abstract][Full Text] [Related]
29. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
[TBL] [Abstract][Full Text] [Related]
30. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.
Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M
Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798
[TBL] [Abstract][Full Text] [Related]
31. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
32. Vaccination coverage rates for 1986.
Pan American Health Organization PAHO
EPI Newsl; 1987 Oct; 9(5):3-5. PubMed ID: 12315298
[TBL] [Abstract][Full Text] [Related]
33. Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally.
Dykens JA; Peterson CE; Holt HK; Harper DM
Front Public Health; 2023; 11():1067299. PubMed ID: 36895694
[TBL] [Abstract][Full Text] [Related]
34. Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean.
Ropero-Álvarez AM; Whittembury A; Kurtis HJ; dos Santos T; Danovaro-Holliday MC; Ruiz-Matus C
Vaccine; 2012 Jan; 30(5):916-21. PubMed ID: 22155136
[TBL] [Abstract][Full Text] [Related]
35. HPV vaccination in Latin America: Coverage status, implementation challenges and strategies to overcome it.
Nogueira-Rodrigues A; Flores MG; Macedo Neto AO; Braga LAC; Vieira CM; de Sousa-Lima RM; de Andrade DAP; Machado KK; Guimarães APG
Front Oncol; 2022; 12():984449. PubMed ID: 36387151
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean.
Almonte M; Albero G; Molano M; Carcamo C; García PJ; Pérez G
Vaccine; 2008 Aug; 26 Suppl 11():L16-36. PubMed ID: 18945400
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
39. Appraisal of willingness to vaccinate daughters with human papilloma virus vaccine and cervical cancer screening uptake among mothers of adolescent students in Abakaliki, Nigeria.
Azuogu BN; Umeokonkwo CD; Azuogu VC; Onwe OE; Okedo-Alex IN; Egbuji CC
Niger J Clin Pract; 2019 Sep; 22(9):1286-1291. PubMed ID: 31489868
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
